STOCK TITAN

Vivos Therapeutics (VVOS) Stock News, Apr-Aug 2022

VVOS NASDAQ

Vivos Therapeutics, Inc. develops and commercializes medical technology and healthcare services for breathing-related sleep disorders, including obstructive sleep apnea and snoring associated with dentofacial abnormalities. Its Complete Airway Repositioning and Expansion (CARE) oral devices have FDA 510(k) clearances for adult OSA patients across severity levels and for moderate-to-severe OSA in children ages 6 to 17.

Company news commonly covers financial results, sleep testing services, treatment-center activity, and the integration of The Sleep Center of Nevada operating assets. Updates also address the shift toward a medical-affiliation distribution model, payer-network status for supported professional practices, collaborations for airway and sleep technologies, and capital actions such as warrant exercises and private placements.

Rhea-AI Summary

Vivos Therapeutics (NASDAQ: VVOS) announced it received a compliance notice from Nasdaq for failing to timely file its Form 10-Q for the quarter ended June 30, 2022. This is due to ongoing reviews of financial statements and discussions over revenue recognition policies. The company has 60 days from August 23, 2022, to file the report to regain compliance. If they fail to do so, Nasdaq may initiate suspension and delisting procedures. The company is working to complete the filing as soon as possible.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.60%
Tags
none
-
Rhea-AI Summary

Vivos Therapeutics (NASDAQ: VVOS) announced a delay in its Q2 2022 financial results, citing a need for a reevaluation of its revenue recognition policy under ASC Topic 606. CEO Kirk Huntsman assured investors that the delay is not indicative of the company's overall health. Despite the delay, Vivos reported strong sales in June with record appliance sales and new provider enrollments. The company is implementing cost-cutting measures and anticipates potential positive cash flow by early 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.00%
Tags
-
Rhea-AI Summary

Vivos Therapeutics (NASDAQ: VVOS) announced the rescheduling of its second quarter financial results originally set for August 15, 2022, due to discussions with its accountants over revenue recognition policies under ASC Topic 606. The new date for the financial results release and conference call is expected on or before August 22, 2022. Vivos specializes in treating dentofacial abnormalities and obstructive sleep apnea through innovative, non-invasive methods.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.02%
Tags
conferences earnings
Rhea-AI Summary

Vivos Therapeutics (NASDAQ: VVOS) is set to announce its Q2 2022 financial results after market close on August 15, 2022. A conference call will follow at 5:00 PM ET that day to discuss the results and company milestones. Vivos specializes in treatments for dentofacial abnormalities and conditions like obstructive sleep apnea (OSA), with its Vivos Method providing a non-invasive solution to approximately 28,000 patients treated globally. The call can be accessed via dial-in or online webcast, with a replay available until August 29, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.92%
Tags
conferences earnings date
-
Rhea-AI Summary

Vivos Therapeutics has received multiple Class I clearances from the Therapeutic Goods Administration in location value="LC/au"Australia for its oral appliances, enabling treatment for obstructive sleep apnea (OSA) in patients of all ages and severities. This regulatory win validates the technology's clinical safety and efficacy. Vivos aims to expand its international market presence, having previously secured clearances in the location value="LC/us"U.S. and location value="LC/ca"Canada. These advancements indicate a significant step forward for addressing the global issue of poor sleep health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
none
-
Rhea-AI Summary

Vivos Therapeutics (NASDAQ: VVOS) has secured an exclusive distribution agreement with GM Instruments, becoming the sole U.S. and Canadian distributor of the NR6 Rhinomanometer, an FDA-approved device for assessing nasal breathing in patients with sleep and breathing issues. This collaboration is expected to enhance Vivos' revenue stream and competitive positioning by providing dentists with critical tools for evaluating and treating conditions like obstructive sleep apnea (OSA). The agreement marks a significant step in Vivos' commitment to improving patient outcomes through innovative diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
none
Rhea-AI Summary

Vivos Therapeutics (NASDAQ: VVOS) presented a retrospective study at the SLEEP 2022 Annual Meeting, highlighting positive results from 786 patients using its proprietary oral appliances. The study found a 4.5% increase in transpalatal widths and an 11.1% increase in airway volume. Notably, 61.6% of the subset of patients showed a reduction of over 50% in the Apnea Hypopnea Index (AHI). Vivos' Complete Airway Repositioning and/or Expansion (CARE) therapy may represent a significant advancement for OSA treatment, offering a finite treatment duration of 12-24 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
none
-
Rhea-AI Summary

Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced two presentations at SLEEP 2022, an event hosted by the Associated Professional Sleep Societies in Charlotte, N.C., from June 4 to 8, 2022. Dr. Seth Heckman will present a retrospective study on non-surgical maxillary expansion on June 6, while Dr. J. Steven Alexander will discuss The Vivos Method's science on June 8. This participation underscores Vivos' commitment to advancing research in addressing dentofacial abnormalities and obstructive sleep apnea.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.08%
Tags
conferences
-
Rhea-AI Summary

Vivos Therapeutics (VVOS) reported a revenue of $3.5 million for Q1 2022, a slight increase from $3.4 million in Q1 2021. Appliance revenue rose 19%, with 2,965 units sold. Gross profit decreased to $2.4 million, resulting in a gross margin of 68%. The company treated approximately 27,000 patients and trained over 1,500 dentists, marking significant growth. Vivos plans to open its third Pneusomnia Sleep Center in May 2022, aiming for more in the year. CEO R. Kirk Huntsman noted improvements starting in March, citing a 28% increase in appliance sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.33%
Tags
Rhea-AI Summary

Vivos Therapeutics, Inc. (NASDAQ: VVOS) will release its financial results for Q1 2022 on May 16, 2022, after market close. A conference call will follow at 5:00 pm ET, where management will discuss results and strategic milestones. The company focuses on innovative solutions for dentofacial abnormalities and mild to moderate obstructive sleep apnea (OSA). The Vivos Method has effectively treated approximately 25,000 patients globally by trained dentists. A replay of the call will be available until May 30, 2022, along with a webcast accessible on Vivos' website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences earnings date

FAQ

What is the current stock price of Vivos Therapeutics (VVOS)?

Vivos Therapeutics (VVOS) last closed at $0.0540.

What is the market cap of Vivos Therapeutics (VVOS)?

The market cap of Vivos Therapeutics (VVOS) is approximately $1.8M.